OncoMatch/Clinical Trials/NCT05952804
IVIG for Infection Prevention After CAR-T-Cell Therapy
Is NCT05952804 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Immune Globulin Infusion (Human), 10% Solution and Anti-CD19 CAR T Cells Preparation for hematologic malignancies.
Treatment: Immune Globulin Infusion (Human), 10% Solution · Anti-CD19 CAR T Cells Preparation — This phase II trial compares the effects of immunoglobulin replacement therapy with a placebo for preventing infectious complications in patients receiving CD19 chimeric antigen receptor (CAR)-T cell therapy. Hypogammaglobulinemia is a common complication in patients who receive CD19 CAR-T cell therapy. This is a condition in which the level of immunoglobulins (antibodies) in the blood is low and the risk of infection is high. Immunoglobulin replacement therapy works by replacing the body's immunoglobulin G (IgG) antibodies with donor blood product derived IgG antibodies that may help prevent infection. IgG antibodies are often depleted as a result of CAR-T therapy. Giving immunoglobulin replacement therapy may prevent infectious complications in patients receiving CD19 CAR-T cell therapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Multiple Myeloma
Myelodysplastic Syndrome
Chronic Lymphocytic Leukemia
Prior therapy
Must have received: CAR-T cell therapy (CD19-CAR T-cell product) — FDA-approved product for hematologic malignancies
Participants will receive an Food and Drug Administration (FDA)-approved CD19-CAR T-cell product for the treatment of hematologic malignancies. Patients receiving an FDA-approved product are eligible even if the product is being administered as part of a clinical trial or expanded access program (e.g., product is 'out of specification'; concomitant anti-tumor treatment such as acalabrutinib)
Cannot have received: bone marrow transplant
SUBSEQUENT INFUSIONS: Receipt of bone marrow transplant (allogeneic or autologous)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope Cancer Center · Duarte, California
- Moffitt Cancer Center · Tampa, Florida
- Massachusetts General Hospital Cancer Center · Boston, Massachusetts
- Memorial Sloan Kettering Cancer Center · New York, New York
- Oregon Health and Science University (OHSU) Knight Cancer Institute · Portland, Oregon
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify